Pancreatic Cancer
Conditions
Keywords
19 gauge, 22 gauge, core tissue
Brief summary
The investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.
Detailed description
Inclusion Criteria 1. Age under 19 years 2. Pregnant women will be excluded. This will be confirmed by self-report Exclusion Criteria 1. Age under 19 years 2. Pregnant women will be excluded. This will be confirmed by self-report
Interventions
PROCEDURE19 gauge
Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
PROCEDURE22 gauge
Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
Sponsors
AdventHealth
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* All patients who are referred to Florida Hospital Center for Interventional Endoscopy for a EUS FNA for core biopsy (19 gauge needle biopsy) who have needle dysfunction (This occurs in about 10% of patients)
Exclusion criteria
* Age under 19 years * Pregnant women will be excluded. This will be confirmed by self-report
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 22 gauge needle | 72 hours | Compare the quality of core tissue specimens obtained between a 19G and 22G needle by evaluating the ability to perform molecular marker studies or immunohistochemistry studies between samples obtained. |
Countries
United States
Outcome results
None listed